

**Comment on "Stability of human rapamycin-expanded CD4<sup>+</sup>CD25<sup>+</sup> T regulatory cells"**  
**Haematologica 2011;96(9):1357-65.**

We recently read with great interest the article by Tresoldi *et al.*<sup>1</sup> in the September 2011 issue of *Haematologica*. Their study examined the stability of human CD4<sup>+</sup> regulatory T (Treg) cells exposed to rapamycin *in vitro* and *in vivo*, and concluded that rapamycin-expanded Treg cells maintained a stable phenotype. We believe that the data from this investigation are interesting but that they do not, however, provide adequate support for their conclusion.

In this study, it was shown that the frequency of FOXP3<sup>+</sup> cells within CD4<sup>+</sup>CD25<sup>+</sup> T cells in the non-rapamycin group of patients declined more markedly than that in the rapamycin group after *in vitro* expansion. Accordingly, the rapamycin-expanded CD4<sup>+</sup>CD25<sup>+</sup> T cells displayed a stronger suppressive activity and contained a smaller fraction of pro-inflammatory cytokine-producing T cells compared to expanded CD4<sup>+</sup>CD25<sup>+</sup> T cells in the absence of rapamycin. These results may be due to the distinct effects of rapamycin on FOXP3<sup>+</sup> Treg cells and effector T cells, because rapamycin was shown to be able to selectively promote *in vitro* expansion of Treg cells while inhibiting proliferation of effector T cells.<sup>2,3</sup> In this study, the initial population (CD4<sup>+</sup>CD25<sup>+</sup> T cells) was contaminated with more than 30% effector T cells. Thus, we could not draw any conclusion about whether rapamycin has an intrinsic role in the stability of Treg cells. Furthermore, recent studies demonstrated that natural Treg cells were instable during *in vitro* culture and could convert to so-called exFOXP3 cells that produced pro-inflammatory cytokines.<sup>4-6</sup> Therefore, the pro-inflammatory cytokines detected in the expanded T cells in this study can be from either preferentially expanded effector T cells or exFOXP3 cells converted from FOXP3<sup>+</sup> Treg cells.

Additionally, the stability of Treg cells *in vivo* remains controversial. Several recent studies have reported that a fraction of FOXP3<sup>+</sup> Treg cells can lose FOXP3 expression after *in vivo* transfer,<sup>7</sup> especially in lymphopenic conditions.<sup>8,9</sup> However, the study by Rubtsov *et al.*<sup>10</sup> reported that FOXP3<sup>+</sup> Treg cells are notably stable under physiological and inflammatory conditions. In this study, Tresoldi and colleagues also tested the stability of Treg cells *in vivo*. However, the article reports that they only displayed the frequency of FOXP3<sup>+</sup> Treg cells after and not before *in vivo* transfer. Furthermore, it was unfortunate that they did not obtain data concerning the number of non-rapamycin expanded FOXP3<sup>+</sup> Treg cells recovered from the injected mice. It is, therefore, difficult to compare the stability of FOXP3<sup>+</sup> Treg cells before and after *in vivo* transfer in the rapamycin group, as well as those cultured with and without rapamycin. Therefore, we think that the data reported in the article cannot offer substan-

tial support for the conclusion that rapamycin fixed the Treg cell phenotype.

Haiqi He and Yi Lv

Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, Shaanxi Province, China

Correspondence: Yi Lv, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University, 277 Yanta West Road, Xi'an 710061, Shaanxi Province, China. E-mail: luyi169@126.com

Key words: T-regulatory cells, *ex vivo* expansion, rapamycin, cell therapy, T-regulatory cell stability.

Citation: Haiqi He, and Yi Lv. Comment on "Stability of human rapamycin-expanded CD4<sup>+</sup>CD25<sup>+</sup> T regulatory cells". *Haematologica* 2011;96(9):1357-1365. *Haematologica* 2012;97(5):e16. doi:10.3324/haematol.2011.061689

The information provided by the authors about contributions from persons listed as authors and in acknowledgments is available with the full text of this paper at [www.haematologica.org](http://www.haematologica.org).

Financial and other disclosures provided by the authors using the ICMJE ([www.icmje.org](http://www.icmje.org)) Uniform Format for Disclosure of Competing Interests are also available at [www.haematologica.org](http://www.haematologica.org).

## References

1. Tresoldi E, Dell'Albani I, Stabilini A, Jofra T, Valle A, Gagliani N, et al. Stability of human rapamycin-expanded CD4<sup>+</sup>CD25<sup>+</sup> T regulatory cells. *Haematologica*. 2011;96(9):1357-65.
2. Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A. Selective survival of naturally occurring human CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> regulatory T cells cultured with rapamycin. *J Immunol*. 2007;178(1):320-9.
3. Strauss L, Czyskowska M, Szajnik M, Mandapathil M, Whiteside TL. Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. *Plos One*. 2009;4(6):e5994.
4. Hoffmann P, Boeld TJ, Eder R, Huehn J, Floess S, Wiczorek G, et al. Loss of FOXP3 expression in natural human CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells upon repetitive *in vitro* stimulation. *Eur J Immunol*. 2009;39(4):1088-97.
5. d'Hennezel E, Yurchenko E, Sgouroudis E, Hay V, Piccirillo CA. Single-cell analysis of the human T regulatory population uncovers functional heterogeneity and instability within FOXP3<sup>+</sup> cells. *J Immunol*. 2011;186(12):6788-97.
6. Zhou XY, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martinez-Llordella M, Ashby M, et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells *in vivo*. *Nat Immunol*. 2009;10(9):1000-7.
7. Hori S. Developmental plasticity of Foxp3<sup>+</sup> regulatory T cells. *Curr Opin Immunol*. 2010;22(5):575-82.
8. Duarte JH, Zelenay S, Bergman ML, Martins AC, Demengeot J. Natural Treg cells spontaneously differentiate into pathogenic helper cells in lymphopenic conditions. *Eur J Immunol*. 2009;39(4):948-55.
9. Komatsu N, Mariotti-Ferrandiz ME, Wang Y, Malissen B, Waldmann H, Hori S. Heterogeneity of natural Foxp3<sup>+</sup> T cells: A committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. *Proc Natl Acad Sci USA*. 2009;106(6):1903-8.
10. Rubtsov YP, Nies RE, Josefowicz S, Li L, Darce J, Mathis D, et al. Stability of the regulatory T cell lineage *in vivo*. *Science*. 2010;329(5999):1667-71.